Necrotising Enterocolitis Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Necrotising Enterocolitis Market is Segmented By Treatment Type (Pharmacological Therapy, Surgical Intervention, Supportive Care), By Diagnosis (Laboratory Tests, Imaging Techniques), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Necrotising Enterocolitis Market Size
Market Size in USD
CAGR5.6%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 5.6% |
| Market Concentration | High |
| Major Players | AbbVie, AstraZeneca, Baxter International, Bristol-Myers Squibb, Fresenius Kabi |
please let us know !
Necrotising Enterocolitis Market Analysis
The Global Necrotising Enterocolitis Market is estimated to be valued at USD 7.10 Billion in 2024 and is expected to reach USD 10.41 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.6% from 2024 to 2031. Necrotising enterocolitis is a gastrointestinal disease primarily affecting premature infants. The increasing number of premature births and the subsequently rising incidence of NEC is a major driver for market growth.
Key factors boosting the demand for NEC treatment and management options include growing awareness among patients and care providers, rising per capita healthcare expenditure in developing nations, and increasing investment by leading market players in developing novel treatment alternatives. Moreover, the rising availability of advanced parenteral nutrition and therapeutics for managing NEC complications is also helping to drive the overall market size over the forecast period.